Herbal Modulators of JAK/STAT Signalling in Chronic Inflammatory and Autoimmune Disorders: An Integrative Approach

Background: Janus kinase/signal transducer and activator of transcription (JAK/STAT) is a key signaling protocol operating in the regulation of immune cells, cytokine communication and inflammation. The JAK/STAT pathway has been implicated in the pathogenesis of several chronic inflammatory and autoimmune diseases, including Rheumatoid Arthritis (RA), psoriasis, Inflammatory Bowel Disease (IBD), and Systemic Lupus Erythematosus (SLE). While pharmacological JAK inhibitors (e.g., tofacitinib, ruxolitinib) have shown therapeutic efficacy, their long-term use is often limited by adverse effects, high costs, and immunosuppressive risks. Over the last few years, a growing body of evidence has highlighted the potential of herbal formulations and plant-derived bioactive compounds as safe, effective, and multi-target modulators of the JAK/STAT pathway. Phytochemicals (curcumin, resveratrol, berberine, and andrographolide) have been observed to affect key actors of this pathway (by inhibiting JAK kinases, STAT activation, and upstream proinflammatory cytokines downregulation). Aim: The aim is to systematically explore the molecular mechanisms of herbal modulators acting on JAK/STAT signalling, their relevance in disease-specific contexts, and the evidence from preclinical and clinical studies. The review dwells on the new methods that are being developed to comprehend the polypharmacological aspect of such compounds, such as network pharmacology, systems biology, and molecular docking. Res ult: Integrating herbal therapeutics into JAK/STAT-targeted strategies offers a promising complementary approach to conventional therapies. Nevertheless, more clinical research and standardisation of the composition, as well as safety profiling, are required to confirm their usage in treatment. Conclusion: The present integrative review will inform future research, which would aim at the utilisation of herbal bioactives in the chronic inflammatory and autoimmune disease managemen

View article page

Download PDF